Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Markets & Finance

Baird Ups Rating on IMS Health

Robert W. Baird raised its investment recommendation on IMS Health(RX) to outperform from neutral, after one of largest shareholders of VNU, which plans to acquire IMS Health, said Friday that it did not support the proposed merger.

Analyst Eric Coldwell said that VNU shareholders' dissent has increased regarding VNU's proposed IMS Health purchase, as Templeton Global Advisors, Fidelity, and Knight Vinke are now opposed. If the deal falls apart, the analyst sees limited downside risk to a stand-alone IMS Health (perhaps $23), while upside potential is substantial (potentially $35) on a strong fundamental outlook. He notes that if the deal is completed, he believes IMS Health would still earn attractive return from its value at Friday's close.

blog comments powered by Disqus